Axel Grothey, MD
It is still debatable which EGFR or VEGF inhibitors provide the greatest benefit when added to chemotherapy in the first-line setting of metastatic colorectal cancer (mCRC), but the identification of RAS
, and microsatellite instability (MSI) has helped physicians to refine treatment decisions.
State of the Science Summit™, Grothey, an oncologist at Sanford Burnham Cancer Center, discussed sidedness and first- and second-line treatments for patients with mCRC.
OncLive: Please provide an overview of your presentation on mCRC.
: I spoke about how to integrate molecular markers into the choice for first-line treatment of patients with CRC. We all intuitively look at patient and tumor characteristics, as well as patient wishes when we choose first-line treatment and the intensity of treatment, but more molecular markers have become available. [We’re using markers] like RAS
mutation status and, more recently, mismatch repair deficiency or MSI-H status to select which treatments we should offer patients.
... to read the full story